Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today

Journal of Biological Regulators and Homeostatic Agents

Volumn 10, Issue 2-3, 1996, Pages 31-53

  Bocci, V ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Antioxidants; Cytokines; Hydrogen peroxide; Ozone; Peroxidation; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; OZONE; REACTIVE OXYGEN METABOLITE;

ALTERNATIVE MEDICINE; BLOOD AUTOTRANSFUSION; CHROMATID; DEGENERATIVE DISEASE; DISINFECTION; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; ERYTHROCYTE; HEALTH CARE COST; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; INFECTION; INTERVERTEBRAL DISK HERNIA; INTRAARTERIAL DRUG ADMINISTRATION; INTRAARTICULAR DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAPLEURAL DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIA; LEUKOCYTE; MUTAGENESIS; OXIDATION; OXIDATIVE STRESS; PHAGOCYTOSIS; RECTAL DRUG ADMINISTRATION; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; TOXICOLOGY; WATER QUALITY; WELLBEING;

EID: 0030417146     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (198)

1. Beaven DW. Alternative medicine a cruel hoax-your money and your life? N Z Med J 1989; 102: 416-7.
2. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246-52.
3. Bocci V Terapia convenzionale o alternativa. Un dilemma da risolvere. Prolusione tenuta per l'inaugurazione del 755o a.a. dell'Università degli Studi di Siena. Annuario dell'Universita' degli Studi di Siena A A 1995/96 1996: (In press)
4. Cassileth BR, Chapman CC. Alternative and complementary cancer therapies. Cancer 1996; 77: 1026-34.
5. Lerner IJ. Against nonscientific treatments. J Lab Clin Med 1996; 127: 242-3.
6. Weleber RG. The Cuban experience. False hope for a cure for retinitis pigmentosa. Arch Ophthalmol 1996; 114: 606-7.
7. Mattassi R. Ozonoterapia. Milano: Organizzazione Editoriale Medico Farmaceutica. 1985: 1-179.
8. Viebahn R. The use of ozone in medicine. 2nd ed. Heidelberg: Karl F. Haug Publishers, 1994: 1-178.
9. Beck EG. Ozone in preventive medicine. In: International Ozone Association, ed. Proceedings Ozone in Medicine, 12th World Congress of the International Ozone Association, 15th to 18th May 1995, Lille France. Tours: Instaprint S.A., 1995, 55-62.
10. Hoigne J, Bader H. Ozonation of water: selectivity and rate of oxidation of solutes. Ozone-Sci Eng 1979; 1: 73-85.
11. Lippman M. Health effects of ozone, a critical review. J Am Air Pollut Control Assoc 1989; 39: 672-95.
12. Devlin RB, McDonnell WF, Mann R, et al Exposure of humans to ambient levels of ozone for 6.6. hours causes cellular and biochemical changes in the lung. Amer J Respir Cell Molec Biol 1991; 4: 72-81
13. Pryor WA. How far does ozone penetrate into the pulmonary air/tissue boundary before it reacts? Free Radical Biol Med 1992; 12: 83-8.
14. Rahman I, Massaro GD, Massaro D. Exposure of rats to ozone: evidence of damage to heart and brain. Free Radical Biol Med 1992; 12: 323-6.
15. Stevens WHM, Conlon PD, O'Byrne PM. Ozone-induced oxygen radical release from bronchoalveolar lavage cells and airway hyper-responsiveness in dogs. J Physiol 1995; 486.1: 257-65.
16. Cross CE, Reznick AZ, Packer L, Davis PA, Suzuki YJ, Halliwell B. Oxidative damage to human plasma proteins by ozone. Free Rad Res Comms 1992; 15: 347-52.
17. Pryor WA. Mechanisms of radical formation from reactions of ozone with target molecules in the lung. Free Radical Biol Med 1994; 17: 451-65.
18. Aris RM, Christian D, Hearne PQ, Kerr K, Finkbeiner WE, Balmes JR. Ozone-induced airway inflammation in human subjects as determined by airway lavage and biopsy. Amer Rev Respir Dis 1993; 148: 1363-72.
19. O'Neill CA, van der Vliet A, Hu M-L, et al. Oxidation of biologic molecules by ozone: the effect of pH. J Lab Clin Med 1993; 122: 497-505.
20. Pryor WA. Ozone in all its reactive splendor. J Lab Clin Med 1993; 122: 483-6.
21. Payr E. Über Ozonbehandlung in der Chirurgie. Münch med Wochenschr 1935; 82: 220-91.
22. Aubours P. Ozon in der Chirurgie. Mem Acad Chir 1940; 65: 1183-92.
23. Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Med Hypotheses 1992; 39: 30-4.
24. Bocci V. Autohaemotherapy after treatment of blood with ozone. A reappraisal. J Int Med Res 1994; 22: 131-44.
25. Wehrli F, Steinbart H. Erfahrungen mit der Haematogenen Oxydations - Therapie (HOT). Ars Medici 1954; 10: 44-51.
26. Jacobs M-Th. Untersuchung uber Zwischenfalle und typische Komplikationen in der Ozon-Sauerstoff-Therapie. OzoNachrichten 1982; 1: 5.
27. Rokitansky O. Klinik und Biochemie der Ozontherapie. Hospitalis 1982; 52: 643-7.
28. Knoch H-G, Klug W. Ozon-Sauerstoff-Therapie der Proktitis. Med Welt 1990; 41: 371-4.
29. Wasser GH. Zerebrale Durchblutungsstörungen. In: Beck. Viebahn-Hänsler, eds. Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg/Lech: Ecomed, 1995, V-6.3 1-V-6.3 12.
30. Werkmeister H. Dekubitalgeschwüre und die Behandlung mit der Ozon-Unterdruckbegasung. In: Beck. Viebahn-Hänsler, eds. Ozon-Handbuck. Grundlagen. Prävention. Therapie. Landsberg/Lech: Ecomed, 1995, V-7.1 1-V-7.1 22.
31. Bocci V, Paulesu L. Studies on the biological effects of ozone 1. Induction of interferon gamma on human leucocytes. Haematologica 1990; 75: 510-5.
32. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Di Stefano A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res 1993; 12: 121-6.
33. Bocci V, Luzzi E, Corradeschi F, Paulesu L. Studies on the biological effects of ozone: 5. Evaluation of immunological parameters and tolerability in normal volunteers receiving ambulatory autohaemotherapy. Biotherapy 1994; 7: 83-90.
34. Bocci V, Luzzi E, Corradeschi F, Silvestri S. Studies on the biological effects of ozone: 6. Production of transforming growth factor β1 by human blood after ozone treatment. J Biol Regulat Homeost Agent 1994; 8: 108-12.
35. Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev 1994; 52: 253-65.
36. Richter C, Gogvadze V, Laffranchi R, et al. Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1995; 1271: 67-74.
37. Halliwell B. How to characterize a biological antioxidant. Free Rad Res Comms 1990; 9: 1-32.
38. Halliwell B, Gutteridge JMC. The antioxidants of human extra-cellular fluids. Arch Biochem Biophys 1990; 280: 1-8.
39. Yu BP, Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994; 74: 139-62.
40. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989; 274: 532-8.
41. Tsuchihashi H, Kigoshi M, Iwatsuki M, Niki E. Action of β-carotene as an antioxidant against lipid peroxidation. Arch Biochem Biophys 1995; 323: 137-47.
42. Madden MC, Friedmen M, Hanley N, et al. Chemical nature and immunotoxicological properties of arachidonic and degradation products formed by exposure to ozone. Environ Health Perspect 1993; 101: 154-64.
43. Pryor WA, Squadrito GL, Friedman M, The cascade mechani sm to explain ozone toxicity: the role of lipid ozonation products. Free Radical Biol Med 1995; 19: 935-41.
44. Esterbauer H. Estimation of peroxidative damage. A critical review. Pathol Biol 1996; 44: 25-8.
45. Los M, Dröge W, Stricker K, Baeuerle PA, Schulze-Osthoff K. Hydrogen peroxide as a potent activator of T lymphocyte functions. Eur J Immunol 1995; 25: 159-65.
46. McCord JM. Superoxide radical: controversies, contradictions, and paradoxes. Proc Soc Exp Biol Med 1995; 209: 112-7.
47. Sen CK, Packer L. Oxidants as stimulators of signal transduction. FASEB J 1996; 10: 709-20.
48. Suzuki YJ, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radical Biol Med 1997; 22: 269-85.
49. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem 1994; 269: 9397-400.
50. May JM, Qu Z-C. Whitesell RR, Cobb CE. Ascorbate recycling in human erythrocytes: role of GSH in reducing dehydroascorbate. Free Radical Biol Med 1996; 20: 543-51.
51. Bocci V, Luzzi E, Corradeschi F, et al. Studies on the biological effects of ozone: 4. Cytokine production and glutathione levels in human erythrocytes. J Biol Regulat Homeost Agent 1993; 7: 133-8.
52. Buckley RD, Hackney JD, Clark K, Posin C. Ozone and human blood. Arch Environ Health 1975; 30: 40-3.
53. Freeman BA, Mudd JB. Reaction of ozone with sulfhydryls of human erythrocytes. Arch Biochem Biophys 1981; 208: 212-20.
54. Chow CK, Tappel AL. Activities of pentose shunt and glycolytic enzymes in lungs of ozone-exposed rats. Arch Environ Health 1973; 26: 205-8.
55. Viebahn-Hänsler R. Einfluss auf den rythrozytenstoffwechsel. In: Ozon-Handbuch. Grundlagen-Prävention-Therapie. Landsberg/Lech: Ecomed, 1995, 1-15.
56. Lenfant C, Torrance J, English E, et al. Effect of altitude on oxygen binding by hemoglobin and on organic phosphate levels. J Clin Invest 1968; 47: 2652-6.
57. Chow CK, Kaneko JJ. Influence of dietary vitamin E on the red cells of ozone-exposed rats. Environ Res 1979; 19: 49-55.
58. Wefers H, Sies H. The protection by ascorbate and glutathione against microsomal lipid peroxidation is dependent on vitamin E. Eur J Biochem 1988; 174: 353-7.
59. Galleano M, Puntarulo S. Role of antioxidants on the erythrocytes resistance to lipid peroxidation after acute iron overload in rats. Biochim Biophys Acta 1995; 1271: 321-6.
60. Edwards CJ, Fuller J. Oxidative stress in erythrocytes. Comp Haematol Int 1996; 6: 24-31.
61. Moncada S, Vane JR. Prostacyclin: homeostatic regulator or biological curiosity? Clin Sci 1981; 61: 369-72.
62. Moncada S. Nitric oxide gas: mediator, modulator, and pathophysiologic entity. J Lab Clin Med 1992; 120: 187-91.
63. Katusic ZS. Superoxide anion and endothelial regulation of arterial tone. Free Radical Biol Med 1996; 20: 443-8.
64. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996; 380: 221-6.
65. Hernàndez F, Menéndez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radical Biol Med 1995; 19: 115-9.
66. Chaudry JH. Use of ATP following shock and ischemia. In: Dubyak GR, Fedan JS, eds. Biological actions of extracellular ATP. Annals of The New York Academy of Sciences. New York: New York Academy of Sciences, 1990, 130-41.
67. Washüttl J, Viebahn R. Immunologische Aspekte bei chronischen Erkrankungen unter Ozon-Sauerstoff-Therapie. OzoNachrichten 1986; 5: 11-5.
68. Washüttl J, Viebahn R, Steiner I. Immunologische Untersuchungen bei chronischen Erkrankungen unter Verabreichung von Ozon-Sauerstoff-Gemischen. OzoNachrichten 1988; 7: 30-6.
69. Chanock SJ, El Benna J, Smith RM, Babior BM. The respiratory burst oxiciase. J Biol Chem 1994; 269: 24519-22.
70. Paulesu L, Luzzi E, Bocci V Studies on the biological effects of ozone: 2. Induction of tumor necrosis factor (TNF-ct) on human leucocytes. Lymphokine Cytokine Res 1991; 10: 409-12.
71. DeForge LE, Fantone JC, Kenney JS, Remick DG. Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood. J Clin Invest 1992; 90: 2123-9.
72. Beck NB, Koenig JQ, Luchtel DL, Altman LC, Orsborn MT, Kenney JS. Ozone can increase the expression of intercellular adhesion molecule-1 and the synthesis of cytokines by human nasal epithelial cells. Inhal Toxicol 1994; 6: 345-57.
73. Arsalane K, Gosset P, Vanhee D, et al. Ozone stimulates synthesis of inflammatory cytokines by alveolar macrophages in vitro. Amer J Respir Cell Molec Biol 1995; 13: 60-8.
74. Takahashi N, Yu X-Y, Schofield BH, et al. Expression of ICAM-1 in airway epithelium after acute ozone exposure in the mouse. J Appl Physiol 1995; 79: 1753-61.
75. Haddad EB, Salmon M, Koto H, Barnes PJ, Adcock I, Chung KF. Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor-kappa b in rat lung: inhibition by corticosteroids. FEBS Lett 1996; 379: 265-8.
76. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-KB transcription factor and HIV-1. EMBO J 1991; 10: 2247-58.
77. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol 1994; 12: 141-79.
78. Anderson MT, Staal FJT, Gitler C, Herzenberg LA, Herzenberg LeA. Separation of oxidant-initiated and redox-regulated steps in the NF-kB signal transduction pathway. Proc Nat Acad Sci USA 1994; 91: 11527-31.
79. Schenk H, Vogt M, Droge W, Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine expression. J Immunol 1996; 156: 765-71.
80. Suzuki Y, Ohsugi K, Ono Y. Oxidative stress triggers tyrosine phosphorylation in B cells through a redox- and inflammatory cytokine-sensitive mechanism. Immunology 1996; 87: 396-401.
81. Bocci V A reasonable approach for the treatment of HIV infection in the early phase with ozonetherapy (autohemotherapy). How inflammatory cytokines may have a therapeutic role. Mediat Inflamm 1994; 3: 315-21.
82. Becker S, Jordan RL, Orlando GS, Koren HS. In vitro ozone exposure inhibits mitogen-induced lymphocyte proliferation and IL-2 production. J Toxicol Environ Health 1989; 26: 469-83.
83. Bocci V. Central nervous system toxicity of interferons and other cytokines. J Biol Regulat Homeost Agent 1988; 3: 107-18.
84. Bocci V Roles of interferon produced in physiological conditions. A speculative review. Immunology 1988; 64: 1-9.
85. Pierce GF, Tarpley JE, Tseng J, et al. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest 1995; 96: 1336-50.
86. Slavin J. The role of cytokines in wound healing. J Pathol 1996; 178: 5-10.
87. Beck LS, DeGuzman L, Lee WP, Xu Y, Siegel MW, Amento EP. One systemic administration of transforming growth factor-β reverses age- or glucocorticoid-impaired wound hea ling. J Clin Invest 1993; 92: 2841-9.
88. Schmid P, Cox D, Bilbe G, et al. TGF-βs and TGF-β type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J Pathol 1993; 171: 191-7.
89. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev 1992; 13: 18-32.
90. van der Vliet A, O'Neill CA, Eiserich JP, Cross CE. Oxidative damage to extracellular fluids by ozone and possible protective effects of thiols. Arch Biochem Biophys 1995; 321: 43-50.
91. Witztum JL. The oxidation hypotheses of atherosclerosis. Lancet 1994; 344: 793-5.
92. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radical Biol Med 1996; 20: 707-27.
93. 1proteinase inhibitor. Amer J Physiol 1994; 266: L593-L611.
94. Bocci V. Determinants of erythrocyte ageing: a reappraisal. Brit J Haematol 1981; 48: 515-22.
95. Goldstein BD, Balchum OJ. Effect of ozone on lipid peroxidation in the red blood cell. Proc Soc Exp Biol Med 1967; 126: 356-9.
96. Peterson ML, Harder S, Rummo N, House D. Effect of ozone on leukocyte function in exposed human subjects. Environ Res 1978; 15: 485-93.
97. Ehrlich R, Findlay JC, Gardner DE. Effects of repeated exposures to peak concentrations of nitrogen dioxide and ozone on resistance to streptococcal pneumonia. J Toxicol Environ Health 1979; 5: 631-42.
98. Fujimaki H. Impairment of humoral immune responses in mice exposed to nitrogen dioxide and ozone mixtures. Environ Res 1989; 48: 211-7.
99. Dziedzic D, White HJ. T-cell activation in pulmonary lymph nodes of mice exposed to ozone. Environ Res 1986; 41: 610-22.
100. Dziedzic D, White HJ. Response of T-cell-deficient mice to ozone exposure. J Toxicol Environ Health 1987; 21: 57-71.
101. Cardile V, Jiang X, Russo A, Casella F, Renis M, Bindoni M. Effects of ozone on some biological activities of cells in vitro. Cell Biol Toxicol 1995; 11: 11-21.
102. Zajicek G. The placebo effect is the healing force of nature. Cancer J 1995; 8: 44-5.
103. Benson H, Friedman R. Harnessing the power of the placebo effect and renaming it "remembered wellness". Annu Rev Med 1996; 47: 193-9.
104. Fetner RH. Chromosome breakage in Vicia faba by ozone. Nature 1958; 181: 504-5.
105. Fetner RH. Ozone-induced chromosome breakage in human cell cultures. Nature 1962; 194: 793-4.
106. Gooch PC, Creasia DA, Brewen JG. The cytogenetic effects of ozone: inhalation and in vitro exposures. Environ Res 1976; 12: 188-95.
107. Merz T, Bender MA, Kerr HD, Kulle TJ. Observations of aberrations in chromosomes of lymphocytes from human subjects exposed at a concentration of 0.5 ppm for 6 and 10 hours. Mutat Res 1975; 3: 299-302.
108. McKenzie WH, Knelson JH, Rumaro NJ, House DE. Cytogenetic effects of inhaled ozone in man. Mutat Res 1977; 48: 95-102.
109. Guerrero RR, Rounds DE, Olson RS, Hackney JD. Mutagenic effects of ozone on human cells exposed in vivo and in vitro based on sister chromatid exchange analysis. Environ Res 1979; 18. 336-46.
110. Sarto F, Viola A. Aberrazioni cromosomiche in soggetti esposti cronicamente ad ozono. G Ital Med Lav 1980; 2: 59-61.
111. Victorin K. Review of the genotoxicity of ozone. Mutat Res 1992; 277: 221-38.
112. Diaz S, Menendez S, Eng L, Fernandez I. No increase in sister chromatid exchanges and micronuclei frequencies in human lymphocytes exposed to ozone in vitro. In: International Ozone Association, ed. Proceedings Ozone in Medicine 12th World Congress of the International Ozone Association, 15th to 18th May 1995, Lille France. Tours: Instaprint S.A., 1995, 43-52.
113. Last JA, Warren DL, Pecquet-Goad E, Witschi H Modification by ozone of lung tumor development in mice. J Nat Cancer Inst 1987; 78: 149-54.
114. Kozumbo WJ, Hanley NM, Agarwal S, Thomas MJ, Madden MC. Products of ozonized arachidonic acid potentiate the formation of DNA single strand breaks in cultured human lung cells. Environ Mol Mutagen 1996; 27: 185-95.
115. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Nat Acad Sci USA 1993; 90: 7915-22.
116. Ernst E, Resch KL. Concept of true and perceived placebo effects. Brit Med J 1995; 311: 551-3.
117. Farber JL, Kyle ME, Coleman JB. Biology of disease. Mechanisms of cell injury by activated oxygen species. Lab Invest 1990; 62: 670-9.
118. Fridovich I. Superoxide radical and Superoxide dismutases. Annu Rev Biochem 1995; 64: 97-112.
119. Carlsson LM, Jonsson J, Edlund T, Marklund SL. Mice lacking extracellular Superoxide dismutase are more sensitive to hyperoxia. Proc Nat Acad Sci USA 1995; 92: 6264-8.
120. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996; 313: 17-29.
121. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Nat Acad Sci USA 1988; 85: 6465-7.
122. Bondy SC. The relation of oxidative stress and hyperexcitation to neurological disease. Proc Soc Exp Biol Med 1995; 208: 337-45.
123. Cohen SM. Olin KL, Feuer WJ, Hjelmeland L, Keen CL, Morse LS. Low glutathione reductase and peroxidase activity in age-related macular degeneration. Brit J Ophthalmol 1994; 78: 791-4.
124. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344: 796-8.
125. Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J 1995; 9: 1173-82.
126. Kangasjärvi J, Talvinen J, Utriainen M, Karjalainen R. Plant defence systems induced by ozone. Plant Cell Environ 1994; 17: 783-94.
127. Ranieri A, D'Urso G, Nali C, Lorenzini G, Soldatini GF. Ozone stimulates apoplastic antioxidant systems in pumpkin leaves. Physiol Plant 1996; 97: 381-7.
128. Sharma YK, Leon J, Raskin I, Davis KR. Ozone-induced responses in Arabidopsis thaliana: the role of salicylic acid in the accumulation of defense-related transcripts and induced resistance. Proc Nat Acad Sci USA 1996; 93: 5099-104
129. Kindwall EP. Hyperbaric Oxygen. Brit Med J 1993; 307: 515-6.
130. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334: 1642-8.
131. Bocci V. May hyperbaric oxigenation be useful to patients with AIDS? J Biol Regulat Homeost Agent 1987; 1: 201.
132. Rahman I, Clerch LB, Massaro D. Rat lung antioxidant enzyme induction by ozone. Amer J Physiol 1991; 260: L412-8.
133. Bocci V. Does ozone therapy normalize the cellular redox balance? Med Hypotheses 1996; 46: 150-4.
134. Khan AU, Wilson T. Reactive oxygen species as cellular messengers. Chem Biol 1995; 2: 437-45.
135. Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci 1996; 21: 83-6.
136. Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992; 119: 598-620.
137. Nakao N, Frodl EM, Widner H, et al. Overexpressing Cu/Zn Superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Medicine 1995; 1: 226-31.
138. Ceballos-Picot I, Merad-Boudia M, Nicole A, et al. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type-place of the extracellular glutathione peroxidase. Free Radical Biol Med 1996; 20: 579-87.
139. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996; 36: 83-106.
140. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995; 358: 1-3.
141. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
142. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 1996; 16: 33-50.
143. Hennekens CH, Buring JE, Peto R. Antioxidant vitamins - benefits not yet proved. N Engl J Med 1994; 330: 1080-1.
144. Schmieden U, Wild A. The contribution of ozone to forest decline. Physiol Plant 1995; 94: 371-8.
145. Victonn K. Review of the genotoxicity of nitrogen oxides. Mutat Res 1994; 317: 43-55.
146. Warren DL, Last JA. Synergistic interaction of ozone and respirable aerosols on rat lungs. III Ozone and sulfuric acid aerosol. Toxicol Appl Pharmacol 1987; 88: 203-16.
147. Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Amer Rev Respir Dis 1989; 140: 531-54.
148. Cantin AM, Fells GA, Hubbard RC, Crystal RG. Antioxidant macromolecules in the epithelial lining fluid of the normal human lower respiratory tract. J Clin Invest 1990; 86: 962-71
149. Sagai M, Ichinose T. Biochemical effects of combined gases of nitrogen dioxide and ozone. IV Changes of lipid peroxidation and antioxidative protective systems in rat lungs upon life span exposure. Toxicology 1991; 66: 121-32.
150. Kelly FJ, Mudway I, Krishna MT, Holgate ST. The free radical basis of air pollution: focus on ozone. Resp Med 1995; 89: 647-56.
151. Carpendale MT, Freeberg J, McLeod Griffiss J. Does Ozone alleviate AIDS diarrhea? J Clin Gastroenterol 1993; 17: 142-5.
152. Quinn CM, Archer GP, Betts WB, O'Neill JG. Dose-dependent dielectrophoretic response of Cryptosporidium oocysts treated with ozone. Lett Appl Microbiol 1996; 22: 224-8.
153. Bocci V The neglected organ: bacterial flora has a crucial immunostimulatory role. Perspect Biol Med 1992; 35: 251-60.
154. Garber GE, Cameron DW, Hawley-Foss N, Greenway D, Shannon ME. The use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. AIDS 1991; 5: 981-4.
155. Popovsky MA, Chaplin HC,Jr., Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of haemotherapy. Transfusion 1992; 32: 589-92.
156. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investigator 1992; 70: 539-44.
157. Miroshin SJ, Kontorshikova CN. The use of ozonetherapy technology in the treatment of modern war surgical trauma. In: The ozone in biology and medicine. 2nd all Russian scientific-practical conference, September 6-8, 1995. Russian association of ozonetherapy, Reshetnikovskaya street 2, Nizhni Novgorod, 603006 Russia. 1995, 16.
158. Shaschova NM. Kachalina TS, Nevmjatullin AL. Application of ozonotherapy in complex treatment of inner female genital inflammatory diseases. In: International Ozone Association, ed. Proceedings Ozone in Medicine, 12th World Congress of the International Ozone Association, 15th to 18th May 1995. Lille France. Tours: Instaprint S.A., 1995, 145-55.
159. Filippi A, Kirschner H. Ozoniertes Wasser zur Desinfektion und Prophylaxe in der Zahn-Mund-Kieferheilkunde. In: Beck, Viebahn-Hänsler, eds. Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg/Lech: Ecomed, 1995, V-12.2 1-V-12.2 12.
160. Wasser GH. Behandlung von Verletzungen mit ozoniertem Wasser. In: Beck, Viebahn-Hänsler, eds. Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg/Lech: Ecomed, 1995, V-7.4 1-V-7.4 8.
161. Bulinin VI, Solod NV, Moshurov IP. The first experience of chronic abscesses and pleura emphyemas treatment by the method of ozonization. In: The ozone in biology and medicine. 2nd all Russian scientific-practical conference, September 6-8, 1995. Russian association of ozonetherapy, Reshetnikovskaya street 2, Nizhni Novgorod, 603006 Russia. 1995, 20.
162. Kudravcev BP, Miroshin SJ, Semyonov SV The use of ozonized solutions in complex treatment of peritonitis. In: The ozone in biology and medicine. 2nd all Russian Scientific-Practical Conference, September 6-8, 1995, Russian Association of Ozonetherapy, Reshetnikovskaya street, 2 - Nizhni Novgorod, 603006 Russia. Nizhni Novgorod: 1995, 20.
163. Kasumjan SA, Lelyanov AD, Guseva ED, Alexeev BP. The ozonetherapy of the acute suppurative infection. In: The ozone in biology and medicine. 2nd all Russian scientific-practical conference, September 6-8, 1995. Russian association of ozonetherapy, Reshetnikovskaya street 2, Nizhni Novgorod, 603006 Russia. 1995, 16.
164. Schulz S. The role of ozone/oxygen in clindamycin-associated enterocolitis in the Djungarian hamster (Phodopus sungorus sungorus). Lab Anun 1986; 20: 41-8.
165. Sporn MB, Roberts AB. A major advance m the use of growth factors to enhance wound healing. J Clin Invest 1993; 92: 2565-6.
166. Hoofnagle JH, Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56.
167. Macllwain C. NIH FDA seek lessons from hepatitis B drug trial deaths. Nature 1993; 364: 275.
168. Akey D, Walton TE. Liquid-phase study of ozone inactivation of Venezuelan Equine Encephalomyelitis virus. Appl Environ Microbiol 1985; 50: 882-6.
169. Shinriki N, Ishizaki K, Yoshizaki T, Miura K, Ueda T. Mechanism of inactivation of tobacco mosaic virus with ozone Wat Res 1988; 22: 933-8.
170. Carpendale MTF, Freeberg JK. Ozone inactivates HIV at noncytotoxic concentrations. Antivir Res 1991; 16: 281-92.
171. Wells KH, Latino J, Gavalchin J, Poiesz BJ. Inactivation of human immunodeficiency virus type 1 by ozone in vitro. Blood 1991; 78: 1882-90.
172. Fausto N, Laird AD, Webber EM. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995; 9: 1527-36.
173. Schwarz KB. Oxidative stress during viral infection: a review. Free Radical Biol Med 1996; 21: 641-9.
174. Konrad H. Ozone therapy for herpes simplex and herpes zoster. In: International Ozone Association, ed. Proceedings Ozone in Medicine, 12th World Congress of the International Ozone Association, 15th to 18th May 1995, Lille, France. Tours: Instaprint S.A., 1995, 187-94.
175. Roederer M, Staal FJT, Raju PA, Ela SW, Herzenberg LeA, Herzenberg LA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Nat Acad Sci USA 1990; 87: 4884-8.
176. Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Nat Acad Sci USA 1991; 88: 986-90.
177. Bergamini A, Capozzi M, Ghibelli L, et al. Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells. J Clin Invest 1994; 93: 2251-7.
178. Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995; 14: 546-54.
179. Sweet F, Kao M-S, Lee S-CD, Hagar WL, Sweet WE. Ozone selectively inhibits growth of human cancer cells. Science 1980; 209: 931-3.
180. Zabel W. Ganzheitsbehandlung der Geschwulsterkrankungen. Hippokrates 1960; 31: 751-60.
181. Varro J. Über das Krebsproblem und seine Therapie. Ztschr int Med Ges f Blut u Geschwulstkrankheiten 1966; 4. 5-6.
182. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
183. Arnason BGW. Interferon beta in multiple sclerosis. Neurology 1993; 43: 641-3.
184. Brandes ME, Allen JB, Ogawa Y, Wahl SM. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108-13.
185. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81: 2964-71.
186. Ruscetti F, Varcsio L, Ochoa A, Ortaldo J. Pleiotropic effects of transforming growth factor-β on cells of the immune system. In: Georgiev VS. Yamaguchi H, eds. Immunomodulating drugs. Annals of The New York Academy of Sciences, vol. 685. New York: The New York Academy of Sciences, 1993, 488-500.
187. Wong R, Menendez S, Castañer J, Pérez P, Abreu A. Ozonetherapy in ischemic cardiopathy. In: International Ozone Association, ed. Proceedings Ozone in Medicine 12th World Congress of the International Ozone Association, 15th to 18th May 1995, Lille France. Tours: Instaprint 1995, 73-7.
188. Verrazzo G, Coppola L, Luongo C, et al. Hyperbaric oxygen, oxygen-ozone therapy, and rheologic parameters of blood in patients with peripheral occlusive arterial disease. Undersea Hyperbar Med 1995; 22: 17-22.
189. Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Nat Acad Sci USA 1995; 92: 954-8.
190. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Nat Acad Sci USA 1996; 93: 2696-701.
191. Gomez Moraleda MA. Ozone therapy in the functional recovery from diseases involving damage to central nervous system cells. In: International Ozone Association, ed. Proceedings Ozone in Medicine 12th World Congress of the International Ozone Association, 15th to 18th May 1995, Lille. France. Tours: Instaprint S.A., 1995, 111-23.
192. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. Beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168-71.
193. Riva Sanseverino E, Meduri RA, Pizzino A, Prantera M, Martini E. Effects of oxygen-ozone therapy on age-related degenerative retinal maculopathy, Panminerva Med 1990; 32: 77-84.
194. Berson EL, Remulla JFC, Rosner B, Sandberg MA, Weigel-DiFranco C Evaluation of patients with retinitis pigmentosa receiving electric stimulation, ozonated blood and ocular surgery in Cuba. Arch Ophthaimol 1996; 114: 560-3.
195. Riva Sanseverino E. Knee-joint disorders treated by oxygenozone therapy. Eur Medicophysica 1989; 25: 163-70.
196. Siemsen C-H. Ozon-Anwendung bei akuten und chronischen Gelenkerkrankungen. In: Beck, Viebahn-Hänsler. eds. Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg/Lech: Ecomed. 1995, V-9.2 1-V-9.2 14.
197. Ernst E. Complementary medicine: from quackery to science? J Lab Clin Med 1996; 127: 244-5.
198. Bocci V. Ozone: a mixed blessing. New mechanisms of the action of ozone on blood cells make ozonated major autohaemotherapy (MAH) a rational approach. Forsch Komplementärmed 1996; 3: 25-33.